GlassScriptPhysician profile
Kimberly D Benko
NPI 1720002637
$964.58
in general payments reported to CMS, 2019-2025
22 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.12 · 2022: $160 · 2023: $291 · 2024: $210 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $203.60 | 2021-2024 | Shingrix, Bexsero, Arexvy |
| Edwards Lifesciences Corporation | $141.63 | 2023 | Sapien 3 Ultra Resilia |
| Astellas Pharma US INC | $73.30 | 2021-2024 | Veozah |
| Cranial Technologies, INC | $53.41 | 2024-2025 | Doc Band |
| Pfizer INC. | $53.04 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $48.23 | 2024-2025 | Capvaxive, Gardasil 9, Vaxelis |
| Lilly USA, LLC | $46.80 | 2025 | Mounjaro, Zepbound |
| Alk-Abello, INC | $39.09 | 2025 | Neffy, Odactra, Grastek |
| Sanofi Pasteur INC. | $38.18 | 2022-2024 | |
| Novo Nordisk INC | $32.03 | 2024-2025 | Ozempic, Rybelsus |
| Medtronic, INC. | $31.58 | 2023 | Venaseal |
| Kaleo, INC. | $29.47 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.40 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.39 | 2024 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $20.63 | 2023 | Flumist Quadrivalent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.65 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.45 | 2024 | Jardiance |
| Supernus Pharmaceuticals, INC. | $17.30 | 2024 | Qelbree |
| Exact Sciences Corporation | $14.94 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.35 | 2022 | |
| Inspire Medical Systems, INC. | $13.95 | 2025 | Inspire |
| Genentech USA, INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Benko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.